Status:
COMPLETED
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
Lead Sponsor:
Pfizer
Collaborating Sponsors:
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-89 years
Phase:
PHASE1
Brief Summary
This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo. ...
Eligibility Criteria
Inclusion
- Diagnosis of probable Alzheimer's Disease with MMSE score of 16-26, and brain MRI consistent with the diagnosis of Alzheimer's Disease
- Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.
- Caregiver will participate and be able to attend clinic visits with patient
Exclusion
- Significant neurological disease other than Alzheimer's Disease
- Major psychiatric disorder
- Contraindication to undergo brain MRI (e.g., pacemaker, CSF shunt, or foreign metal objects in the body)
- Women of childbearing potential
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT01193608
Start Date
September 1 2010
End Date
October 1 2013
Last Update
February 23 2017
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Early Phase Investigational Center
Escondido, California, United States, 92025
2
Synergy Clinical Research Center of Escondido
Escondido, California, United States, 92025
3
MD Clinical
Hallandale, Florida, United States, 33009
4
Franck's Pharmacy
Ocala, Florida, United States, 34471